A phase II trial with patients with HIV/AIDS and various cancers: Patients with Kaposis Sarcoma (9 patients), Lung (12 patients), melanoma (3 patients), hypernephroma (1 patient); and pancreatic cancer (1 patient). Patients were treated with MENK for up to 12 months over a wide range of doses. Increases in T-cell subsets were observed after 1 to 2 weeks of treatment.
The T cell subsets included CD3, CD4, CD8 and CD2 positive cells. Increase in blastogenic responses to PHA, ConA, and pokeweed mitogen was observed. A major finding was an increase in interleukin 2 receptor expression. NK cell activity was measured in 14 patients of these patients and an increased NK activity was present in 12 or 14 patients. No toxicity attributable to MENK was observed and a significant reduction in lymph node size after 8 and 12 weeks of treatment.